» Articles » PMID: 29144724

Structure-Based Analysis of Boronic Acids As Inhibitors of Acinetobacter-Derived Cephalosporinase-7, a Unique Class C β-Lactamase

Abstract

Acinetobacter baumannii is a multidrug resistant pathogen that infects more than 12 000 patients each year in the US. Much of the resistance to β-lactam antibiotics in Acinetobacter spp. is mediated by class C β-lactamases known as Acinetobacter-derived cephalosporinases (ADCs). ADCs are unaffected by clinically used β-lactam-based β-lactamase inhibitors. In this study, five boronic acid transition state analog inhibitors (BATSIs) were evaluated for inhibition of the class C cephalosporinase ADC-7. Our goal was to explore the properties of BATSIs designed to probe the R1 binding site. K values ranged from low micromolar to subnanomolar, and circular dichroism (CD) demonstrated that each inhibitor stabilizes the β-lactamase-inhibitor complexes. Additionally, X-ray crystal structures of ADC-7 in complex with five inhibitors were determined (resolutions from 1.80 to 2.09 Å). In the ADC-7/CR192 complex, the BATSI with the lowest K (0.45 nM) and greatest Δ T (+9 °C), a trifluoromethyl substituent, interacts with Arg340. Arg340 is unique to ADCs and may play an important role in the inhibition of ADC-7. The ADC-7/BATSI complexes determined in this study shed light into the unique recognition sites in ADC enzymes and also offer insight into further structure-based optimization of these inhibitors.

Citing Articles

Activity of Organoboron Compounds against Biofilm-Forming Pathogens.

Konaklieva M, Plotkin B Antibiotics (Basel). 2024; 13(10).

PMID: 39452196 PMC: 11504661. DOI: 10.3390/antibiotics13100929.


Synthesis of a Novel Boronic Acid Transition State Inhibitor, MB076: A Heterocyclic Triazole Effectively Inhibits -Derived Cephalosporinase Variants with an Expanded-Substrate Spectrum.

Powers R, June C, Fernando M, Fish E, Maurer O, Baumann R J Med Chem. 2023; 66(13):8510-8525.

PMID: 37358467 PMC: 10350917. DOI: 10.1021/acs.jmedchem.3c00144.


Sulfonamidoboronic Acids as "Cross-Class" Inhibitors of an Expanded-Spectrum Class C Cephalosporinase, ADC-33, and a Class D Carbapenemase, OXA-24/40: Strategic Compound Design to Combat Resistance in .

Introvigne M, Beardsley T, Fernando M, Leonard D, Wallar B, Rudin S Antibiotics (Basel). 2023; 12(4).

PMID: 37107006 PMC: 10135033. DOI: 10.3390/antibiotics12040644.


Drug‑resistant : From molecular mechanisms to potential therapeutics (Review).

Wu H, Xiao Z, Lv X, Huang H, Liao C, Hui C Exp Ther Med. 2023; 25(5):209.

PMID: 37090073 PMC: 10119666. DOI: 10.3892/etm.2023.11908.


Class C β-Lactamases: Molecular Characteristics.

Philippon A, Arlet G, Labia R, Iorga B Clin Microbiol Rev. 2022; 35(3):e0015021.

PMID: 35435729 PMC: 9491196. DOI: 10.1128/cmr.00150-21.


References
1.
Wyrembak P, Babaoglu K, Pelto R, Shoichet B, Pratt R . O-aryloxycarbonyl hydroxamates: new beta-lactamase inhibitors that cross-link the active site. J Am Chem Soc. 2007; 129(31):9548-9. DOI: 10.1021/ja072370u. View

2.
Romagnoli C, Caselli E, Prati F . Synthesis of 1,2,3-triazol-1-yl-methaneboronic acids via click chemistry: an easy access to a new potential scaffold for protease inhibitors. European J Org Chem. 2015; 2015(5):1075-1083. PMC: 4527660. DOI: 10.1002/ejoc.201403408. View

3.
Tian G, Adams-Haduch J, Taracila M, Bonomo R, Wang H, Doi Y . Extended-spectrum AmpC cephalosporinase in Acinetobacter baumannii: ADC-56 confers resistance to cefepime. Antimicrob Agents Chemother. 2011; 55(10):4922-5. PMC: 3186995. DOI: 10.1128/AAC.00704-11. View

4.
McCoy A, Grosse-Kunstleve R, Adams P, Winn M, Storoni L, Read R . Phaser crystallographic software. J Appl Crystallogr. 2009; 40(Pt 4):658-674. PMC: 2483472. DOI: 10.1107/S0021889807021206. View

5.
Perichon B, Goussard S, Walewski V, Krizova L, Cerqueira G, Murphy C . Identification of 50 class D β-lactamases and 65 Acinetobacter-derived cephalosporinases in Acinetobacter spp. Antimicrob Agents Chemother. 2013; 58(2):936-49. PMC: 3910822. DOI: 10.1128/AAC.01261-13. View